饮食和循环中的丁酸盐独立与糖尿病的功能有关:双队列分析
Leying Zhao1,2, Cong Zhao1,2, Aoshuang Li3
1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Frontiers in nutrition
|October 15, 2025
概括
从饮食或血清中获得更高的丁酸盐水平,与糖尿病成年人的更好的功能有关. 这表明,准肠道微生物群可能会预防糖尿病病.
科学领域:
- 肠道微生物群和代谢过程
- 的平衡和脏疾病.
- 代谢学和人类健康
背景情况:
- 丁酸盐是一种肠道微生物群的代谢物,通过抗炎和免疫调节作用影响脏平衡.
- 关于丁酸盐和功能,存在有限的大规模人类研究,特别是在糖尿病人群中.
- 糖尿病病 (DKD) 是糖尿病的一个主要并发症,需要研究保护策略.
研究的目的:
- 研究糖尿病成年人中丁酸盐暴露与功能之间的关联.
- 评估与功能标志物相关的饮食酸盐摄入量和血清酸盐水平.
- 在糖尿病病的背景下探索肠轴.
主要方法:
- 分析了NHANES (1999-2018) 中7723名患有糖尿病的成年人的数据,评估了饮食中的丁酸盐摄入量,估计的淋巴细胞过率 (eGFR) 和白尿.
- 外部验证使用中国队列 (70名DKD患者) 通过UPLC-MS/MS测量血清丁酸和异丁酸,评估与eGFR和24小时尿蛋白的关联.
- 应用多变量回归,受限立方线建模和具有调查权重的子组分析.
主要成果:
- 在NHANES队列中,更高的酸盐摄入量与更高的eGFR (β=1.61,p=0.02) 独立相关,显示出显著的非线性剂量反应.
- 在NHANES队列中,没有观察到酸盐饮食摄入量和白蛋白尿之间的显著关联.
- 血清丁酸盐 (β=0.05,p=0.02) 和异丁酸盐 (β=0.15,p=0.02) 在中国队列中与EGFR积极相关,糖尿病和CKD的参与者也有类似的发现.
结论:
- 这项双队列研究提供了第一个流行病学证据,将更高的丁酸盐水平 (饮食或血清) 与糖尿病成年人功能改善联系起来.
- 研究结果强调了肠-轴在糖尿病病中的重要性.
- 增强内源性丁酸盐生产可能代表糖尿病病的新性保护策略.
相关概念视频
01:27Urinary Tract Calculi IV: Nutrition Therapy and Prevention
354
Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
354
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
189
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
189
01:24Chronic Kidney Disease II: Clinical Manifestations
552
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
552
01:29Renal Regulation of Acid-Base Balance
1.5K
Metabolic reactions in the body produce nonvolatile acids, such as sulfuric acid, which generate an acid load of approximately 1 mEq of H+ per kilogram of body weight daily. Excreting H+ in the urine is essential to balance this acid load.
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
1.5K
01:28Chronic Kidney Disease III: Interprofessional Care
339
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
339
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
246
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
246